Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Quality assessment for therapeutic drug monitoring in AIDS Clinical Trials Group (ACTG 5146): a multicenter clinical trial.

DiFrancesco R, Rosenkranz S, Mukherjee AL, Demeter LM, Jiang H, DiCenzo R, Dykes C, Rinehart A, Albrecht M, Morse GD.

Ther Drug Monit. 2010 Aug;32(4):458-66. doi: 10.1097/FTD.0b013e3181e4427a.

2.

A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study.

Albrecht M, Mukherjee AL, Tierney C, Morse GD, Dykes C, Klingman KL, Demeter LM.

HIV Clin Trials. 2011 Jul-Aug;12(4):201-14. doi: 10.1310/HCT1204-201.

3.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
4.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
5.

Clinical benefit of interventions driven by therapeutic drug monitoring.

Rendón A, Núñez M, Jiménez-Nácher I, González de Requena D, González-Lahoz J, Soriano V.

HIV Med. 2005 Sep;6(5):360-5.

6.

The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems.

Schoenenberger JA, Aragones AM, Cano SM, Puig T, Castello A, Gomez-Arbones X, Porcel JM.

Ther Drug Monit. 2013 Feb;35(1):71-7. doi: 10.1097/FTD.0b013e3182791f8c.

PMID:
23188184
7.

Therapeutic drug monitoring of antiretrovirals for people with HIV.

Kredo T, Van der Walt JS, Siegfried N, Cohen K.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007268. doi: 10.1002/14651858.CD007268.pub2. Review.

PMID:
19588422
8.

Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?

Aarnoutse RE, Schapiro JM, Boucher CA, Hekster YA, Burger DM.

Drugs. 2003;63(8):741-53. Review.

PMID:
12662123
9.
10.

The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patients.

Demeter LM, Mukherjee AL, DiFrancesco R, Jiang H, DiCenzo R, Bastow B, Rinehart AR, Morse GD, Albrecht M.

HIV Clin Trials. 2008 Jan-Feb;9(1):61-72. doi: 10.1310/hct0901-61.

11.

Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.

Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, Mellors JW; AIDS Clinical Trials Group 398 Study Team..

JAMA. 2002 Jul 10;288(2):169-80.

PMID:
12095381
12.

Therapeutic drug monitoring in children with HIV/AIDS.

Fraaij PL, Rakhmanina N, Burger DM, de Groot R.

Ther Drug Monit. 2004 Apr;26(2):122-6. Review.

PMID:
15228151
13.

Protease inhibitor plasma concentrations in HIV antiretroviral therapy.

Justesen US.

Dan Med Bull. 2008 Nov;55(4):165-85. Review.

PMID:
19232158
14.

Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories.

Holland DT, DiFrancesco R, Stone J, Hamzeh F, Connor JD, Morse GD; Adult and Pediatric AIDS Clinical Trials Group Pharmacology Laboratory Committees, Pediatric AIDS Clinical Trials Group..

Antimicrob Agents Chemother. 2004 Mar;48(3):824-31.

15.

A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients.

Best BM, Goicoechea M, Witt MD, Miller L, Daar ES, Diamond C, Tilles JG, Kemper CA, Larsen R, Holland DT, Sun S, Jain S, Wagner G, Capparelli EV, McCutchan JA, Haubrich RH; California Collaborative Treatment Group 578 Study Team..

J Acquir Immune Defic Syndr. 2007 Dec 1;46(4):433-42.

PMID:
17786128
16.

Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.

van Heeswijk RP, Veldkamp A, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM.

Antivir Ther. 2001 Dec;6(4):201-29. Review.

PMID:
11878403
17.

Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals.

Burger D, Hugen P, Reiss P, Gyssens I, Schneider M, Kroon F, Schreij G, Brinkman K, Richter C, Prins J, Aarnoutse R, Lange J; ATHENA Cohort Study Group..

AIDS. 2003 May 23;17(8):1157-65.

PMID:
12819517
18.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
19.

Therapeutic drug monitoring in HIV infection: current status and future directions.

Back D, Gatti G, Fletcher C, Garaffo R, Haubrich R, Hoetelmans R, Kurowski M, Luber A, Merry C, Perno CF.

AIDS. 2002 Mar;16 Suppl 1:S5-37. Review.

PMID:
12035820
Items per page

Supplemental Content

Support Center